You are here » Home » Companies » Company Overview » Pfizer Ltd

Pfizer Ltd.

BSE: 500680 Sector: Health care
NSE: PFIZER ISIN Code: INE182A01018
BSE LIVE 15:42 | 23 Aug 1808.95 55.45
(3.16%)
OPEN

1799.95

HIGH

1829.25

LOW

1768.90

NSE 15:55 | 23 Aug 1808.35 45.05
(2.55%)
OPEN

1805.00

HIGH

1828.95

LOW

1765.70

OPEN 1799.95
PREVIOUS CLOSE 1753.50
VOLUME 18744
52-Week high 2055.00
52-Week low 1625.00
P/E 41.54
Mkt Cap.(Rs cr) 8,276
Buy Price 1812.00
Buy Qty 4.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1799.95
CLOSE 1753.50
VOLUME 18744
52-Week high 2055.00
52-Week low 1625.00
P/E 41.54
Mkt Cap.(Rs cr) 8,276
Buy Price 1812.00
Buy Qty 4.00
Sell Price 0.00
Sell Qty 0.00

Pfizer Ltd. (PFIZER) - Chairman Speech

Company chairman speech

We have had a good year on the back of a strong performance of our top brands.

Dear Shareholders

This is my first communication to you after taking up the position of Managing Directorof your Company. The management has always enjoyed your confidence as we have steeredPfizer Limited on a path of consistent growth. I hope to continue receiving your supportas we take new initiatives and sustain the momentum that has been built over the pastyears.

We have had a good year on the back of a strong performance of our top brands. Ourbroad product portfolio allows us to serve as many as 15 therapy areas with a number ofhousehold names amongst them that continue to be preferred by physicians patients andcustomers.

Our strategy has been to focus on these ‘Power Brands' and their strategicextensions. We achieved this through impactful and innovative ways of reaching newprescribers and sustaining the preference of those who prescribe our products today. Iwould like to call out our multi-channel marketing strategy as an example of theseefforts. Deployed during the year this approach utilizes new age digital tools to betterengage with physicians – building differentiation in a competitive and clutteredenvironment. As a result of these and other measures your Company was successful inplacing nine of its top ten brands in leadership positions in their respective representedproduct markets.

This year has not been without challenges. In particular the revision of the NationalList of Essential Medicines (NLEM) and ensuing price controls have impacted the Industryand your Company. We expect the full impact of these expanded price controls to be visibleduring the next year. On the positive side however the revised NLEM brings in greaterclarity than before on the criteria for inclusion and the specific dosage and deliveryforms of drugs to be included. The order of the Ministry of Health against certain fixeddose combinations has also posed significant challenges. While your Company supports theintent of the Government to weed out irrational combinations the approach of notsegregating products that have due central and state approvals and the lack of opportunityfor manufacturers to present their case has been challenged. This matter remainssub-judice and we await the ruling of the Hon'ble Court.

Within the Company our greatest emphasis during the year has been on our field force.Your Company has earmarked the year starting January 2016 as one dedicated to its FieldColleagues. This initiative has seen an unprecedented effort by the leadership team toconnect with motivate and equip the field force with the right tools to win.

I am proud to state that your Company pursued an active Corporate Responsibility agendaduring the year. Having identified shared objectives with the Government this year welaunched our flagship CSR initiative – the Pfizer IIT-Delhi Innovation and IPProgram. In doing so your Company has made its contribution to the Prime Minister'sagenda of Startup India Stand up India – an initiative that encourages and supportsthe pursuit of healthcare innovations within the country. Our Swachh Vidyalaya program toowas scaled up this year. Pfizer colleagues worked together to build sanitation facilitiesin schools across Maharashtra – an effort that we believe has changed young lives ina fundamental way.

In summary our strategy has remained consistent from the year before – a focus onour strong brands an emphasis on engaging innovatively with our physicians and being anadvocate for positive external policies while being reasonably resilient to challenges.The results of 2015-16 demonstrate the effectiveness of this strategy.

Your Company's strengths are its product portfolio the quality and commitment of itspeople its relationships with external stakeholders and most importantly the ethical andcompliant manner in which it operates. We intend to leverage these fundamentals to deliverconsistent growth and performance.

I thank you for your continued encouragement as always and look forward to yourconstant support in our journey of charting success.

Yours sincerely

S. Sridhar

Managing Director